10-Q: ALX Oncology Reports First Quarter 2024 Financial Results and Provides Business Update

ALX Oncology's first quarter 2024 results show increased research and development spending and a net loss, while highlighting progress in clinical trials and collaborations.

Summary

• ALX Oncology reported a net loss of $35.6 million for the first quarter of 2024, compared to a net loss of $30.2 million for the same period in 2023.
• Research and development expenses increased to $31.7 million, up from $24.8 million in the first quarter of 2023, driven by increased clinical trial activity and manufacturing costs.
• General and administrative expenses decreased to $6.0 million from $7.4 million in the same period last year.
• The company's cash, cash equivalents, and investments totaled $184.5 million as of March 31, 2024.
• ALX Oncology believes its current resources will fund operations into the first quarter of 2026.
• The company continues to advance its lead product candidate, evorpacept, through multiple clinical trials and collaborations.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is positive clinical data and progress in development programs, the increased net loss and reliance on future capital raises temper the overall sentiment. The company is making progress but faces financial challenges.

Positives

• The company reported positive interim Phase 2 clinical data from the ASPEN-06 trial, showing a significant improvement in overall response rate compared to the control group.
• The Phase 1/2 investigator-sponsored trial of evorpacept in combination with R2 in R/R B-NHL showed promising results with a high overall response rate.
• The FDA cleared the IND for ALTA-002, allowing the company to begin a Phase 1 clinical trial.
• The company successfully raised $3.0 million through its ATM offering program during the quarter and an additional $26.2 million subsequent to the quarter end.
• The company believes its existing cash, cash equivalents, investments, and ability to draw down an additional $40 million of its term loan will be sufficient to fund operations into early 2026.

Negatives

• The company reported a net loss of $35.6 million for the first quarter of 2024, an increase from the $30.2 million loss in the same period of 2023.
• Research and development expenses increased significantly, primarily due to increased clinical trial activity and manufacturing costs.
• The company's cash and cash equivalents decreased from $22.4 million at the end of 2023 to $14.0 million at the end of the first quarter of 2024.
• The company's mechanistic hypothesis for combining evorpacept with hypomethylation agents was not supported by clinical trial data.

Risks

• The company is substantially dependent on the success of evorpacept, which is still in clinical development.
• Clinical trials are expensive, time-consuming, and may not demonstrate adequate safety and efficacy.
• The company relies on third-party manufacturers for clinical supplies, which could lead to delays or insufficient quantities.
• The company's debt and compliance with the terms of its loan agreement could restrict its ability to operate its business.
• The company's business could be adversely impacted by outbreaks or public health crises, geopolitical unrest, and instability in the financial services sector.
• The company may require substantial additional capital to finance its operations, which may not be available on acceptable terms or at all.

Future Outlook

The company believes its existing cash, cash equivalents, investments, and ability to draw down an additional $40 million of its term loan will be sufficient to fund operations into early 2026. The company expects to continue to incur significant expenses and increasing operating losses for the foreseeable future as it advances its product candidates through clinical trials and pursues regulatory approvals.

Management Comments

• Management expects to incur additional losses in the future to conduct product candidate research and development and to conduct pre-commercialization activities.
• Management recognizes the need to raise additional capital to fully implement its business plan.
• Management believes that the existing capital resources will be sufficient to fund the projected operating requirements for at least the next twelve months.

Industry Context

This announcement reflects the ongoing challenges and progress in the immuno-oncology field, where companies are investing heavily in research and development to bring new therapies to market. The positive clinical data from ALX Oncology's trials, particularly in combination therapies, are notable in the context of the broader industry's focus on combination approaches to cancer treatment. The discontinuation of Gilead's magrolimab trials highlights the risks and uncertainties inherent in drug development, and the need for rigorous testing of mechanistic hypotheses.

Comparison to Industry Standards

• The 52% overall response rate in the ASPEN-06 trial compares favorably to historical data for ramucirumab + paclitaxel (28% ORR) and ENHERTU (41% ORR) in similar patient populations.
• The 94% overall response rate and 83% complete response rate in the Phase 1/2 IST of evorpacept in combination with R2 in R/R B-NHL are promising compared to typical outcomes in this patient population.
• The company's approach of combining evorpacept with anti-cancer antibodies and PD-1/PD-L1 inhibitors aligns with current industry trends in immuno-oncology.
• The company's decision to discontinue combinations based on the hypomethylation agent mechanism is consistent with Gilead's decision to discontinue its Phase 3 magrolimab trials in AML and MDS due to lack of efficacy.

Related Party Transactions

• The company recorded a nominal amount and $0.1 million as research and development costs in relation to the research and development services agreement with Tallac.
• The company recorded $0.4 million and $0.7 million as R&D costs in relation to the collaboration agreement with Tallac.
• The company made a $1.0 million milestone payment to the stockholders of ScalmiBio, including $0.3 million to the company's former CEO and current CSO and President, and $0.6 million to another employee of the company.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may benefit from the company's growth and development.
• Patients may benefit from the development of new cancer therapies.
• Creditors may be impacted by the company's debt obligations and financial performance.
• Suppliers may benefit from the company's ongoing research and development activities.

Next Steps

• Continue advancing evorpacept through multiple clinical trials.
• Pursue regulatory approval of evorpacept in solid tumors and hematological malignancies.
• Continue discovery and preclinical and clinical development efforts, including collaborations with Sanofi, Tallac, Jazz, and Quantum Leap.
• Advance the development of ALTA-002 into a Phase 1 clinical trial.
• Continue to add operational, financial and management information systems to support ongoing operations as a public company.

Key Dates

Keywords

evorpacept, immuno-oncology, clinical trials, cancer therapy, CD47, ALTA-002, oncology, biotechnology, drug development, antibody, checkpoint inhibitor